Loading…
Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.
Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.
Sells prescription drugs to hospitals and specialist doctors, largely in Japan, and earns outside Japan through its US subsidiary NS Pharma, which markets Viltepso for Duchenne muscular dystrophy. A smaller functional-food ingredients business sits alongside the drugs.
In one line: A mid-size Japanese pharma with a rare-disease focus, like a smaller Alexion.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug designations and patents provide extended exclusivity in niche therapeutic areas.
Headquarters: Kyoto, Japan · Founded: 1919 · Employees: 2,309
Size Nippon Shinyaku (4516.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 589th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,340 on 6 Nov 2026.
Performance Over six months the shares fell 30.3%, against -16.6% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 12.2% over the last twelve months (peer median +15.8%); the operating margin is 18.5% (peer median -12.7%).
Valuation It trades at 7.7× forward earnings against a peer median of 24.2× (cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥180B | ¥171B | ¥160B | ¥148B | ¥144B |
| Revenue growth | — | +7% | +8% | +3% | — |
| Gross profit | ¥118B | ¥112B | ¥108B | ¥97.0B | ¥87.3B |
| EBITDA | ¥40.2B | ¥39.7B | ¥42.8B | ¥36.4B | ¥34.3B |
| Net income | ¥31.6B | ¥29.7B | ¥32.6B | ¥25.9B | ¥22.8B |
| Free cash flow | ¥18.9B | ¥24.2B | ¥32.8B | ¥11.2B | ¥20.5B |
| Capital expenditure | ¥5.07B | ¥3.78B | ¥34.8B | ¥9.65B | ¥11.7B |
| Total debt | ¥2.56B | ¥2.57B | ¥2.72B | ¥2.87B | ¥2.66B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nippon Shinyaku 4516.T | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% |
| Astellas Pharma 4503.T | $28.2B | +11% | +19% | 23% | 11.6× | -11.0% |
| ONO Pharmaceutical 4528.T | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4516.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -7.0% | 9th highest of 21 |
| 6-month return | -30.3% | -16.6% | 8th lowest of 21 |
| Distance from 52-week high | -48.8% | -40.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +12.2% | +15.8% | 8th lowest of 18 |
| Operating margin | 18.5% | -12.7% | 4th highest of 18 |
| Forward P/E | 7.7× | 24.2× | cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -17.5% | 3.7% | least demanding of 7 |
| Growth delivered (Del g) | +7.0% | +11.9% | 3rd lowest of 7 |
| Hurdle (Req g minus delivered) | -24.5 pp | -5.0 pp | least demanding of 7 |
| ROIC minus cost of capital | +5.3 pp | -8.1 pp | 4th highest of 18 |
| EV / EBITDA | 3.9× | 14.3× | cheapest of 6 |
| Net debt / EBITDA | -1.7× | 1.4× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |